324 related articles for article (PubMed ID: 31606796)
1. How We Treat Recurrent Glioblastoma Today and Current Evidence.
Chaul-Barbosa C; Marques DF
Curr Oncol Rep; 2019 Oct; 21(10):94. PubMed ID: 31606796
[TBL] [Abstract][Full Text] [Related]
2. New Immunotherapeutic Approaches for Glioblastoma.
Vázquez Cervantes GI; González Esquivel DF; Gómez-Manzo S; Pineda B; Pérez de la Cruz V
J Immunol Res; 2021; 2021():3412906. PubMed ID: 34557553
[TBL] [Abstract][Full Text] [Related]
3. Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma.
Maxwell R; Jackson CM; Lim M
Curr Treat Options Oncol; 2017 Aug; 18(8):51. PubMed ID: 28785997
[TBL] [Abstract][Full Text] [Related]
4. Current Immunotherapies for Glioblastoma Multiforme.
Huang B; Li X; Li Y; Zhang J; Zong Z; Zhang H
Front Immunol; 2020; 11():603911. PubMed ID: 33767690
[TBL] [Abstract][Full Text] [Related]
5. Current Advances in Immunotherapy for Glioblastoma.
Mende AL; Schulte JD; Okada H; Clarke JL
Curr Oncol Rep; 2021 Jan; 23(2):21. PubMed ID: 33496872
[TBL] [Abstract][Full Text] [Related]
6. Emerging immunotherapies for glioblastoma.
Desai R; Suryadevara CM; Batich KA; Farber SH; Sanchez-Perez L; Sampson JH
Expert Opin Emerg Drugs; 2016 Jun; 21(2):133-45. PubMed ID: 27223671
[TBL] [Abstract][Full Text] [Related]
7. Advances in Immunotherapy for Glioblastoma Multiforme.
Huang B; Zhang H; Gu L; Ye B; Jian Z; Stary C; Xiong X
J Immunol Res; 2017; 2017():3597613. PubMed ID: 28299344
[TBL] [Abstract][Full Text] [Related]
8. An Innovative Immunotherapy Vaccine with Combination Checkpoint Blockade as a First Line Treatment for Glioblastoma in the Context of Current Treatments.
Coxon AT; Johanns TM; Dunn GP
Mo Med; 2020; 117(1):45-49. PubMed ID: 32158049
[TBL] [Abstract][Full Text] [Related]
9. Prospects of immune checkpoint modulators in the treatment of glioblastoma.
Preusser M; Lim M; Hafler DA; Reardon DA; Sampson JH
Nat Rev Neurol; 2015 Sep; 11(9):504-14. PubMed ID: 26260659
[TBL] [Abstract][Full Text] [Related]
10. Combining Tumor Vaccination and Oncolytic Viral Approaches with Checkpoint Inhibitors: Rationale, Pre-Clinical Experience, and Current Clinical Trials in Malignant Melanoma.
Cavalcante L; Chowdhary A; Sosman JA; Chandra S
Am J Clin Dermatol; 2018 Oct; 19(5):657-670. PubMed ID: 29961183
[TBL] [Abstract][Full Text] [Related]
11. Novel Immunotherapeutics for Treatment of Glioblastoma: The Last Decade of Research.
Khansur E; Shah AH; Lacy K; Komotar RJ
Cancer Invest; 2019; 37(1):1-7. PubMed ID: 30632816
[TBL] [Abstract][Full Text] [Related]
12. Prospects of biological and synthetic pharmacotherapies for glioblastoma.
Altshuler DB; Kadiyala P; Nuñez FJ; Nuñez FM; Carney S; Alghamri MS; Garcia-Fabiani MB; Asad AS; Nicola Candia AJ; Candolfi M; Lahann J; Moon JJ; Schwendeman A; Lowenstein PR; Castro MG
Expert Opin Biol Ther; 2020 Mar; 20(3):305-317. PubMed ID: 31959027
[No Abstract] [Full Text] [Related]
13. Gene and viral therapy for glioblastoma: a review of clinical trials and future directions.
Mohyeldin A; Chiocca EA
Cancer J; 2012; 18(1):82-8. PubMed ID: 22290261
[TBL] [Abstract][Full Text] [Related]
14. What next for newly diagnosed glioblastoma?
Domingo-Musibay E; Galanis E
Future Oncol; 2015; 11(24):3273-83. PubMed ID: 26558493
[TBL] [Abstract][Full Text] [Related]
15. Re-irradiation after gross total resection of recurrent glioblastoma : Spatial pattern of recurrence and a review of the literature as a basis for target volume definition.
Straube C; Elpula G; Gempt J; Gerhardt J; Bette S; Zimmer C; Schmidt-Graf F; Meyer B; Combs SE
Strahlenther Onkol; 2017 Nov; 193(11):897-909. PubMed ID: 28616821
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy for Brain Tumors.
Hoang-Minh LB; Mitchell DA
Curr Treat Options Oncol; 2018 Oct; 19(11):60. PubMed ID: 30311004
[TBL] [Abstract][Full Text] [Related]
17. Current strategies for vaccination in glioblastoma.
Dutoit V; Migliorini D; Dietrich PY
Curr Opin Oncol; 2019 Nov; 31(6):514-521. PubMed ID: 31403483
[TBL] [Abstract][Full Text] [Related]
18. The need for paradigm shift: prognostic significance and implications of standard therapy-related systemic immunosuppression in glioblastoma for immunotherapy and oncolytic virotherapy.
Stepanenko AA; Sosnovtseva AO; Valikhov MP; Chernysheva AA; Abramova OV; Naumenko VA; Chekhonin VP
Front Immunol; 2024; 15():1326757. PubMed ID: 38390330
[TBL] [Abstract][Full Text] [Related]
19. A randomized controlled phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy of newly diagnosed glioblastoma (GlioVax): study protocol for a randomized controlled trial.
Rapp M; Grauer OM; Kamp M; Sevens N; Zotz N; Sabel M; Sorg RV
Trials; 2018 May; 19(1):293. PubMed ID: 29801515
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy as a New Therapeutic Approach for Brain and Spinal Cord Tumors.
Medikonda R; Pant A; Lim M
Adv Exp Med Biol; 2023; 1394():73-84. PubMed ID: 36587382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
